| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911310 | Lung Cancer | 2012 | 8 Pages |
Abstract
ALK gene amplification is a nonrandom and clonally related event in a subset of PSC, but its biologic rationale deserves further investigation. KRAS mutation could represent a novel tool for therapy of such so deadly tumors with MEK inhibitors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Giuseppe Pelosi, Patrizia Gasparini, Alberto Cavazza, Giulio Rossi, Paolo Graziano, Mattia Barbareschi, Federica Perrone, Massimo Barberis, Masayuki Takagi, Toshiaki Kunimura, Tetsuya Yamada, Yukio Nakatani, Ugo Pastorino, Paolo Scanagatta,